Harvard Bioscience regenerative subsidiary planning IPO

Harvard Bioscience Inc. (NASDAQ:HBIO) said its Harvard Apparatus Regenerative Technology Inc. subsidiary plans to raise up to $20 million in an IPO on NASDAQ underwritten by Summer Street. The IPO is expected to close early next year, after which the subsidiary will be spun out to develop Harvard Bioscience's regenerative medicine technologies. Harvard Bioscience, which will retain its research tools business, will own at least 80% of Harvard Apparatus. ...